Should I Buy KMDA? KMDA 2026 Analysis

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

8.370

1 Day change

-3.13%

52 Week Range

9.150

Analysis Updated At

2026/01/26

Kamada Ltd (KMDA) is not a strong buy for a beginner, long-term investor at this time. While the company has shown positive financial performance and analysts have raised the price target, the technical indicators and options data suggest a neutral to slightly bearish sentiment. Additionally, there are no significant positive catalysts or proprietary trading signals to support an immediate buy decision.

Technical Analysis

The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 53.993, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support is at 7.732, and resistance is at 8.297. The stock is trading near its support level, but no strong upward momentum is evident.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data shows very low put-call ratios, indicating limited bearish sentiment, but overall trading volume is too low to draw strong conclusions.

Technical Summary

Sell

Buy

Positive Catalysts

Analysts raised the price target from $11 to $13 and maintained a Buy rating. The company has refocused on core products, eliminating distractions from an unfruitful clinical trial.

Neutral/Negative Catalysts

No recent news or significant trading trends from hedge funds, insiders, or Congress. Technical indicators show bearish momentum, and stock trend analysis predicts potential declines in the next week and month.

Financial Performance

In Q3 2025, Kamada's revenue increased by 12.63% YoY to $47.01M, net income rose by 37.10% YoY to $5.296M, EPS grew by 28.57% YoY to $0.09, and gross margin improved by 1.82% YoY to 42.04%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

H.C. Wainwright raised the price target to $13 from $11 and maintained a Buy rating, citing the company's refocus on core products as a positive development.

2 Analyst Rating

Wall Street analysts forecast KMDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KMDA is 14 USD with a low forecast of 13 USD and a high forecast of 15 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 8.640

Low

Averages

High

Current: 8.640

Low

Averages

High

H.C. Wainwright

Buy

maintain

$11 -> $13

AI Analysis

2025-12-09

Reason

H.C. Wainwright

Price Target

$11 -> $13

AI Analysis

2025-12-09

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on Kamada to $13 from $11 and keeps a Buy rating on the shares. The company decided to discontinue its Phase 3 inhaled alpha-1 antitrypsin deficiency clinical trial based on the results of the planned interim futility analysis, the analyst tells investors in a research note. The firm says the decision helps to refocus the company on its core products and eliminates a "long over-hanging distraction that was unlikely to be fruitful."

Benchmark

Robert Wasserman

Strong Buy

Initiates

$15

2025-03-21

Reason

Benchmark

Robert Wasserman

Price Target

$15

2025-03-21

Initiates

Strong Buy

Reason

Benchmark analyst Robert Wasserman initiated coverage of Kamada with a Buy rating and $15 price target.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for KMDA

Unlock Now

KMDA Should I Buy

KMDA Should I Buy

Should You Buy Kamada Ltd (KMDA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch